These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 22008761

  • 1. Experience with rifabutin replacing rifampin in the treatment of tuberculosis.
    Horne DJ, Spitters C, Narita M.
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1485-9, i. PubMed ID: 22008761
    [Abstract] [Full Text] [Related]

  • 2. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?
    Loeliger A, Suthar AB, Ripin D, Glaziou P, O'Brien M, Renaud-Thery F, Crowley S, Williams B, Ridzon R, Granich R, Gilks C.
    Int J Tuberc Lung Dis; 2012 Jan; 16(1):6-15. PubMed ID: 21819645
    [Abstract] [Full Text] [Related]

  • 3. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
    Li J, Munsiff SS, Driver CR, Sackoff J.
    Clin Infect Dis; 2005 Jul 01; 41(1):83-91. PubMed ID: 15937767
    [Abstract] [Full Text] [Related]

  • 4. Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex.
    Berrada ZL, Lin SY, Rodwell TC, Nguyen D, Schecter GF, Pham L, Janda JM, Elmaraachli W, Catanzaro A, Desmond E.
    Diagn Microbiol Infect Dis; 2016 Jun 01; 85(2):177-81. PubMed ID: 27036978
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Rifampin-resistance-associated mutations in the rifampin-resistance-determining region of the rpoB gene of Mycobacterium tuberculosis clinical isolates in Shanghai, PR China.
    Guo Y, Cao X, Yang J, Wu X, Liu Y, Wan B, Hu L, Wang H, Yu F.
    J Med Microbiol; 2021 Mar 01; 70(3):. PubMed ID: 33507146
    [Abstract] [Full Text] [Related]

  • 8. The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis.
    Jo KW, Ji W, Hong Y, Lee SD, Kim WS, Kim DS, Shim TS.
    Respir Med; 2013 Feb 01; 107(2):292-7. PubMed ID: 23199704
    [Abstract] [Full Text] [Related]

  • 9. Comparative analysis of the drug-drug interaction between immunosuppressants, safety and efficacy of rifabutin from rifampicin-based Anti-TB treatment in living donor liver transplant recipients with active tuberculosis.
    Wang YC, Salvador NG, Lin CC, Wu CC, Lin TL, Lee WF, Chan YC, Chen CL, Co JS, Encarnacion DD.
    Biomed J; 2021 Dec 01; 44(6 Suppl 2):S162-S170. PubMed ID: 35300949
    [Abstract] [Full Text] [Related]

  • 10. The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
    Tan Y, Hu Z, Zhao Y, Cai X, Luo C, Zou C, Liu X.
    J Clin Microbiol; 2012 Jan 01; 50(1):81-5. PubMed ID: 22075601
    [Abstract] [Full Text] [Related]

  • 11. [Use of rifabutin in cases of toxicity to rifampicin].
    Moreno González B, Rodríguez Blanco A, Rodríguez Barrientos R, Vidal Pérez JL, Noguerado Asensio A.
    Rev Clin Esp; 2005 Sep 01; 205(9):430-2. PubMed ID: 16194477
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice.
    Reddy MV, Luna-Herrera J, Daneluzzi D, Gangadharam PR.
    Tuber Lung Dis; 1996 Apr 01; 77(2):154-9. PubMed ID: 8762850
    [Abstract] [Full Text] [Related]

  • 15. [Clinical experience using rifabutin for treating infection with Mycobacterium tuberculosis in elderly Japanese patients].
    Morimoto K, Yoshiyama T, Kuse M, Okumura M, Sasaki Y, Yoshimori K, Ogata H, Kurashima A, Kudoh S.
    Kekkaku; 2013 Aug 01; 88(8):625-8. PubMed ID: 24044166
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice.
    Ji B, Truffot-Pernot C, Lacroix C, Raviglione MC, O'Brien RJ, Olliaro P, Roscigno G, Grosset J.
    Am Rev Respir Dis; 1993 Dec 01; 148(6 Pt 1):1541-6. PubMed ID: 8256897
    [Abstract] [Full Text] [Related]

  • 17. Comment on: The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.
    Akkerman OW, Alffenaar JWC.
    J Antimicrob Chemother; 2019 Mar 01; 74(3):834. PubMed ID: 30508093
    [No Abstract] [Full Text] [Related]

  • 18. Rifabutin: where do we stand in 2016?
    Crabol Y, Catherinot E, Veziris N, Jullien V, Lortholary O.
    J Antimicrob Chemother; 2016 Jul 01; 71(7):1759-71. PubMed ID: 27009031
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic dilemma: treatment outcomes of tuberculosis patients with inconsistent rifampicin susceptibility.
    Pang Y, Ruan YZ, Zhao J, Chen C, Xu CH, Su W, Huan ST, Li RZ, Zhao YL, Chin DP, Wang LX.
    Int J Tuberc Lung Dis; 2014 Mar 01; 18(3):357-62. PubMed ID: 24670576
    [Abstract] [Full Text] [Related]

  • 20. Determination of the Critical Concentration of Rifabutin for Susceptibility Testing Using the Proportion Method with Löwenstein-Jensen Medium against Mycobacterium Tuberculosis Isolates.
    Dai G, Chen S, Dong L, Li YX, Huo F, Shang Y, Huang H.
    Lab Med; 2019 Jul 16; 50(3):292-297. PubMed ID: 30806669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.